| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 21.43 mm | 21.43 mm | 21.43 mm | 21.43 mm | 21.43 mm | 21.43 mm |
| Cash burn (monthly) | 812.33 k | 521.92 k | 8.79 mm | 7.47 mm | 7.56 mm | 6.78 mm |
| Cash used (since last report) | 4.13 mm | 2.65 mm | 44.64 mm | 37.96 mm | 38.39 mm | 34.47 mm |
| Cash remaining | 17.30 mm | 18.78 mm | -23.21 mm | -16.53 mm | -16.96 mm | -13.04 mm |
| Runway (months of cash) | 21.3 | 36.0 | -2.6 | -2.2 | -2.2 | -1.9 |
| 13F holders | Current |
|---|---|
| Total holders | 142 |
| Opened positions | 32 |
| Closed positions | 21 |
| Increased positions | 51 |
| Reduced positions | 33 |
| 13F shares | Current |
|---|---|
| Total value | 498.65 bn |
| Total shares | 248.78 mm |
| Total puts | 600.00 |
| Total calls | 55.60 k |
| Total put/call ratio | 0.0 |
| Largest owners | Shares | Value |
|---|---|---|
| NEA Management | 24.47 mm | $75.13 bn |
| Growth Equity Opportunities 17 | 24.47 mm | $100.33 mm |
| Farallon Capital Partners | 17.23 mm | $48.23 mm |
| Bain Capital Life Sciences Investors | 14.57 mm | $44.72 bn |
| Bain Capital Life Sciences Fund II | 14.57 mm | $69.04 mm |
| TCG Crossover Management | 12.36 mm | $37.95 bn |
| Vestal Point Capital | 10.78 mm | $33.08 bn |
| TCG Crossover GP I | 10.00 mm | $31.40 mm |
| BlackRock | 9.59 mm | $29.44 bn |
| Frazier Life Sciences Management | 8.66 mm | $26.59 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 13 Feb 25 | Robert Matthew Lutz | Common Stock | Payment of exercise | Dispose F | No | No | 2.83 | 38,263 | 108.28 k | 361,737 |
| 16 Dec 24 | Hawkins Richard J | Common Stock | Sell | Dispose S | No | No | 3.3211 | 8,000 | 26.57 k | 67,241 |
| 12 Dec 24 | Nevan C Elam | Common Stock | Grant | Acquire A | No | No | 0 | 40,000 | 0.00 | 62,500 |
| 12 Dec 24 | McCracken Joseph S | Common Stock | Grant | Acquire A | No | No | 0 | 40,000 | 0.00 | 250,837 |
| 12 Dec 24 | van Es-Johansson An | Common Stock | Grant | Acquire A | No | No | 0 | 40,000 | 0.00 | 62,500 |
| 12 Dec 24 | Hawkins Richard J | Common Stock | Grant | Acquire A | No | No | 0 | 40,000 | 0.00 | 75,241 |
